(Q36105726)

12 August 2017

1 reference

title

Calcium antagonists and beta-blockers: impact on cardiovascular and cerebrovascular events (English)

1 reference

12 August 2017

Franz H Messerli

1 reference

12 August 2017

language of work or name

1 reference

1 January 2004

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

18-27

1 reference

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke. The Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Effect of Calcium Antagonists on Plasma Norepinephrine Levels, Heart Rate, and Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Influence of heart rate on mortality among persons with hypertension: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Antihypertensive treatment of patients with diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Left ventricular hypertrophy and mortality--results from the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Chronotherapeutics: a surge of ideas

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Circadian variation in the timing of stroke onset: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980075-9

7 January 2021

10.1016/S1098-3597(04)80075-9

Identifiers

DOI

1 reference

12 August 2017

1 reference